$VXRT $NVAX $INO Hard to say how the MRNA news is going to play out on top of the NYT article. In the past, we’ve seen funding for one vaccine company both help and hurt the stock prices of competitors. Tomorrow’s impact will all depend on whether the market sees this as a bullish sign for the vaccine sector in general, or if it sees MRNA’s success as coming at the expense of its competitors. I don’t have a good guess at this point.
  • 1
1 Like